

Immunomodulatory effects of cannabinoids in human T-lymphocytes

Anja Schinwald, Francesc Galban-Horcajo, Eva Malone, Paula Smith. Edinburgh Napier University, Edinburgh, United Kingdom.

Background: Circulating levels of endocannabinoids are elevated in obese and hyperglycaemic patients and may contribute to immune dysfunction in obesity and diabetes. Cannabinoids have been shown to evoke both pro- and anti-inflammatory responses, acting via CB₁ and CB₂ receptors on immune cells. In the present study we compared the responses of human T-cells to varying concentrations (0.1–1000nM) of endocannabinoids (anandamide and 2-arachidonoylglycerol, 2-AG), a phytocannabinoid (Δ^9 -tetrahydrocannabinol, Δ^9 -THC), and a synthetic CB₂ receptor agonist (JWH-015).

Methods: Lymphocytes were isolated from the peripheral blood of healthy male and female subjects ($n=12$; aged 20-30 years), and cell surface expression of the T-cell activation marker CD69 was assessed on CD3⁺, CD4⁺ and CD8⁺ T-cells following 24 h cannabinoid treatment, using four-colour flow cytometry. In addition, lymphocyte CB₁ and CB₂ receptor expression was measured by real-time RT-PCR. The human Jurkat T-cell line was used to assess the effects of cannabinoids on T cell migration, to the chemokine CXCL12, in single-well Boyden chemotaxis chambers ($n=4-5$).

Results: Endocannabinoids did not significantly alter T-cell activation, however, Δ^9 -THC increased the proportion of CD3⁺ T-cells expressing CD69 (from 1 ± 0 to 3.59 ± 1.54 ; $P=0.09$) at low concentrations (0.1nM), and decreased (from 1 ± 0 to 0.39 ± 0.22 ; $P<0.05$) at high concentrations (100nM). JWH-015 suppressed PMA-induced %CD69 expression at all concentrations tested (from 1 ± 0 to between 0.28 ± 0.21 and 0.66 ± 0.00 ; $P<0.05$). There were no significant differences between CD4⁺ and CD8⁺ T-cell phenotypes. CD69 was not correlated with CB₁ or CB₂ receptor mRNA expression. Endocannabinoids did not affect T-cell migration to CXCL12, while Δ^9 -THC and JWH-015 reduced T-cell migration in a concentration-dependent manner (e.g. for Δ^9 -THC: $100\pm 0\%$ cell migration score for control versus $93\pm 7\%$ at 1nM; $46\pm 8\%$ at 10nM; $27\pm 19\%$ at 100nM; and $0\pm 0\%$ at 1000nM; $P<0.01$).

Conclusions: These data reveal differences in the immunomodulatory effect of endo- versus synthetic and phyto-cannabinoids and concentration-dependent effects, with low Δ^9 -THC concentrations stimulating and high concentrations inhibiting T-cell activation. Studies using selective CB₁ and CB₂ receptor antagonists are warranted to confirm the receptor involved in mediating these responses.